Amylin Pharmaceuticals ( AMLN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.4%. By the end of trading, Amylin Pharmaceuticals rose 49 cents (1.9%) to $25.91 on light volume. Throughout the day, 2.7 million shares of Amylin Pharmaceuticals exchanged hands as compared to its average daily volume of 5.3 million shares. The stock ranged in a price between $25.18-$25.95 after having opened the day at $25.42 as compared to the previous trading day's close of $25.42. Other companies within the Health Care sector that increased today were: Conceptus ( CPTS), up 23.6%, Warner Chilcott ( WCRX), up 16.1%, NuPathe ( PATH), up 15.3%, and China Shenghuo Pharmaceutical Holdings ( KUN), up 13.5%. Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin Pharmaceuticals has a market cap of $4.16 billion and is part of the drugs industry. Currently there are four analysts that rate Amylin Pharmaceuticals a buy, three analysts rate it a sell, and eight rate it a hold. TheStreet Ratings rates Amylin Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally weak debt management and feeble growth in its earnings per share.
- You can view the full Amylin Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.